THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD;THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
The present invention provides a compound which is an inhibitor ofsphingolipid biosynthesis for use in the treatmentof a disease which has a secondary Niemann-Pick type C disease like cellularphenotype.